Literature DB >> 8603382

Mxi1 tumor suppressor gene is not mutated in primary pancreatic adenocarcinoma.

D Bartsch1, S L Peiffer, Z Kaleem, S A Wells, P J Goodfellow.   

Abstract

Amplification of the c-myc oncogene occurs in a variety of solid tumors, including pancreatic adenocarcinomas. The MXI1 gene, located at 10q24-q25, may serve to negatively regulate c-myc oncogene activity, and potentially has tumor suppressor function. As such, altered MXI1 function might contribute to tumorigenesis. We examined 40 primary human pancreatic adenocarcinomas for MXI1 mutations. Single-strand conformation variant analysis and direct sequencing of the variants revealed a MXI1 polymorphism in 1 of 40 tumors. No MXI1 mutations were identified. Southern blot analyses did not reveal any gross rearrangements of MXI1. These results suggest that MXI1 is unlikely to play a role in human pancreatic adenocarcinoma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603382     DOI: 10.1016/0304-3835(96)04167-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

Review 1.  The Max network gone mad.

Authors:  T A Baudino; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 2.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 3.  Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.

Authors:  Daniel Diolaiti; Lisa McFerrin; Patrick A Carroll; Robert N Eisenman
Journal:  Biochim Biophys Acta       Date:  2014-05-22

Review 4.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

5.  Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network.

Authors:  J K R Boult; P Tanière; M T Hallissey; M J Campbell; C Tselepis
Journal:  Br J Cancer       Date:  2008-05-20       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.